Loading…
PA-543 Evaluation of host serum biomarkers from successfully treated TB patients presenting with or without persisting lung inflammation – preliminary findings of StatinTB trial
BackgroundDespite the availability of anti-TB treatment, successfully treated TB patients remain with persisting lung inflammation regardless of HIV status. Lung inflammation has been linked with robust or imbalanced host immune responses which exacerbate tissue necrosis. Soluble host biomarkers hav...
Saved in:
Published in: | BMJ global health 2023-12, Vol.8 (Suppl 10), p.A95-A95 |
---|---|
Main Authors: | , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Online Access: | Request full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | BackgroundDespite the availability of anti-TB treatment, successfully treated TB patients remain with persisting lung inflammation regardless of HIV status. Lung inflammation has been linked with robust or imbalanced host immune responses which exacerbate tissue necrosis. Soluble host biomarkers have been shown to correlate with the development of lung inflammation at different stages of anti-TB treatment which further affect sputum conversion in these patients. In our ongoing StatinTB trial (RIA2017T-2004; NCT04147286), we evaluate safety and efficacy of 40 mg atorvastatin to reduce persistent lung inflammation after TB treatment in HIV-/HIV+ adults measured by 18F-FDG-PET/CT. Here we aim to explore the expression profile of host serum biomarkers from successfully treated TB patients with or without persisting lung inflammation.MethodsStudy participants were screened for sputum conversion at month-4 and month-6 of anti-TB treatment. Enrolled participants were subjected to PET/CT scan, where Arm A=TLG |
---|---|
ISSN: | 2059-7908 |
DOI: | 10.1136/bmjgh-2023-EDC.233 |